ESMO 2022 on the NICHE-2 Study: Neoadjuvant Immune Checkpoint Inhibition in Locally Advanced dMMR Colon Cancer | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

ESMO 2022 Conference Coverage

ESMO 2022 on the NICHE-2 Study: Neoadjuvant Immune Checkpoint Inhibition in Locally Advanced dMMR Colon Cancer

By ESMO 2022 Conference Coverage FEATURING Myriam Chalabi

By ESMO 2022 Conference Coverage FEATURING Myriam Chalabi

920 views

September 16, 2022

Comments 0

Login to view comments. Click here to Login